{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:16:02Z","timestamp":1759936562466},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,8,8]],"date-time":"2014-08-08T00:00:00Z","timestamp":1407456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00280-014-2558-x","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T06:59:00Z","timestamp":1407394740000},"page":"751-756","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study"],"prefix":"10.1007","volume":"74","author":[{"given":"Zuleyha","family":"Akgun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sezer","family":"Saglam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serap","family":"Yucel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Gural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emre","family":"Balik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokhan","family":"Cipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyma","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadettin","family":"Kilickap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Okyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra","family":"Kaytan-Saglam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,8]]},"reference":[{"issue":"11","key":"2558_CR1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114\u20131123. doi: 10.1056\/NEJMoa060829","journal-title":"N Engl J Med"},{"issue":"31","key":"2558_CR2","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1200\/JCO.2009.22.0467","volume":"27","author":"MS Roh","year":"2009","unstructured":"Roh MS, Colangelo LH, O\u2019Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27(31):5124\u20135130. doi: 10.1200\/JCO.2009.22.0467","journal-title":"J Clin Oncol"},{"issue":"23","key":"2558_CR3","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1200\/JCO.2010.33.1595","volume":"29","author":"V Valentini","year":"2011","unstructured":"Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M, Bonnetain F, Bosset JF, Bujko K, Cionini L, Gerard JP, Rodel C, Sainato A, Sauer R, Minsky BD, Collette L, Lambin P (2011) Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 29(23):3163\u20133172. doi: 10.1200\/JCO.2010.33.1595","journal-title":"J Clin Oncol"},{"issue":"24","key":"2558_CR4","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1200\/JCO.2005.02.113","volume":"23","author":"JF Bosset","year":"2005","unstructured":"Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L (2005) Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results\u2014EORTC 22921. J Clin Oncol 23(24):5620\u20135627. doi: 10.1200\/JCO.2005.02.113","journal-title":"J Clin Oncol"},{"issue":"4","key":"2558_CR5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","volume":"45","author":"J Schuller","year":"2000","unstructured":"Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45(4):291\u2013297. doi: 10.1007\/s002800050043","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2558_CR6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","volume":"13","author":"RD Hofheinz","year":"2012","unstructured":"Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Muller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13(6):579\u2013588. doi: 10.1016\/S1470-2045(12)70116-X","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"2558_CR7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0959-8049(01)00415-4","volume":"38","author":"C Twelves","year":"2002","unstructured":"Twelves C (2002) Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 38(Suppl 2):15\u201320","journal-title":"Eur J Cancer"},{"issue":"1","key":"2558_CR8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijrobp.2007.12.019","volume":"72","author":"C Capirci","year":"2008","unstructured":"Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, Coco C, Romano M, Mantello G, Palazzi S, Mattia FO, Friso ML, Genovesi D, Vidali C, Gambacorta MA, Buffoli A, Lupattelli M, Favretto MS, La Torre G (2008) Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72(1):99\u2013107. doi: 10.1016\/j.ijrobp.2007.12.019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2558_CR9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-3-662-09355-9_11","volume-title":"Handbook of experimental pharmacology: physiology and pharmacology of biological rhythms","author":"F Levi","year":"1997","unstructured":"Levi F (1997) Chronopharmacology of anticancer agents. In: Redfern PH, Lemmer B (eds) Handbook of experimental pharmacology: physiology and pharmacology of biological rhythms. Springer, Berlin, pp 299\u2013331"},{"issue":"21","key":"2558_CR10","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jnci\/86.21.1608","volume":"86","author":"FA Levi","year":"1994","unstructured":"Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L et al (1994) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86(21):1608\u20131617","journal-title":"J Natl Cancer Inst"},{"key":"2558_CR11","author":"E Bajetta","year":"2013","unstructured":"Bajetta E, Pietrantonio F, Buzzoni R, Ferrario E, Valvo F, Mariani L, Dotti KF, Biondani P, Formisano B, Gevorgyan A, Grassi P, Di Bartolomeo M (2013) Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. Am J Clin Oncol. doi: 10.1097\/COC.0b013e31827ecd1d","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2558_CR12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00066-011-0015-x","volume":"188","author":"N Hodapp","year":"2012","unstructured":"Hodapp N (2012) The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 188(1):97\u201399. doi: 10.1007\/s00066-011-0015-x","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"2558_CR13","first-page":"9","volume":"5","author":"S Saglam","year":"2014","unstructured":"Saglam S, Bugra D, Saglam EK, Asoglu O, Balik E, Yamaner S, Basaran M, Oral EN, Kizir A, Kapran Y, Gulluoglu M, Sakar B, Bulut T (2014) Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4\/N0+ rectal cancer: Istanbul R-01 study. J Gastrointest Oncol 5(1):9\u201317. doi: 10.3978\/j.issn.2078-6891.2013.025","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"2558_CR14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s003840050072","volume":"12","author":"O Dworak","year":"1997","unstructured":"Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12(1):19\u201323","journal-title":"Int J Colorectal Dis"},{"issue":"9","key":"2558_CR15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00066-008-1751-4","volume":"184","author":"J Dunst","year":"2008","unstructured":"Dunst J, Debus J, Rudat V, Wulf J, Budach W, Hoelscher T, Reese T, Mose S, Roedel C, Zuehlke H, Hinke A (2008) Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol 184(9):450\u2013456. doi: 10.1007\/s00066-008-1751-4","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"2558_CR16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","volume":"40","author":"B Reigner","year":"2001","unstructured":"Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40(2):85\u2013104. doi: 10.2165\/00003088-200140020-00002","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2558_CR17","first-page":"941","volume":"4","author":"B Reigner","year":"1998","unstructured":"Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B (1998) Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4(4):941\u2013948","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2558_CR18","first-page":"685","volume":"58","author":"T Ishikawa","year":"1998","unstructured":"Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H (1998) Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58(4):685\u2013690","journal-title":"Cancer Res"},{"issue":"1","key":"2558_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","volume":"27","author":"CM Walko","year":"2005","unstructured":"Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27(1):23\u201344. doi: 10.1016\/j.clinthera.2005.01.005","journal-title":"Clin Ther"},{"issue":"24","key":"2558_CR20","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1016\/0006-2952(88)90349-8","volume":"37","author":"BE Harris","year":"1988","unstructured":"Harris BE, Song RL, He YJ, Soong SJ, Diasio RB (1988) Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochem Pharmacol 37(24):4759\u20134762","journal-title":"Biochem Pharmacol"},{"issue":"15","key":"2558_CR21","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.2000.18.15.2894","volume":"18","author":"S Mani","year":"2000","unstructured":"Mani S, Hochster H, Beck T, Chevlen EM, O\u2019Rourke MA, Weaver CH, Bell WN, White R, McGuirt C, Levin J, Hohneker J, Schilsky RL, Lokich J (2000) Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol 18(15):2894\u20132901","journal-title":"J Clin Oncol"},{"issue":"4","key":"2558_CR22","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1998.16.4.1450","volume":"16","author":"RL Schilsky","year":"1998","unstructured":"Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA III (1998) Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 16(4):1450\u20131457","journal-title":"J Clin Oncol"},{"issue":"6","key":"2558_CR23","doi-asserted-by":"crossref","first-page":"798","DOI":"10.7326\/0003-4819-101-6-798","volume":"101","author":"JJ Lokich","year":"1984","unstructured":"Lokich JJ, Moore C (1984) Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101(6):798\u2013799","journal-title":"Ann Intern Med"},{"key":"2558_CR24","author":"LT Macedo","year":"2014","unstructured":"Macedo LT, Lima JP, Dos Santos LV, Sasse AD (2014) Prevention strategies for chemotherapy-induced hand\u2013foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer. doi: 10.1007\/s00520-014-2129-z","journal-title":"Support Care Cancer"},{"issue":"2","key":"2558_CR25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/1523-1747.ep12480379","volume":"97","author":"WR Brown","year":"1991","unstructured":"Brown WR (1991) A review and mathematical analysis of circadian rhythms in cell proliferation in mouse, rat, and human epidermis. J Invest Dermatol 97(2):273\u2013280","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2558_CR26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00280-006-0302-x","volume":"59","author":"D Santini","year":"2007","unstructured":"Santini D, Vincenzi B, Schiavon G, Di Seri M, Virzi V, Spalletta B, Caricato M, Coppola R, Tonini G (2007) Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemother Pharmacol 59(5):613\u2013620. doi: 10.1007\/s00280-006-0302-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2558_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/annonc\/mdp272","volume":"21","author":"C Qvortrup","year":"2010","unstructured":"Qvortrup C, Jensen BV, Fokstuen T, Nielsen SE, Keldsen N, Glimelius B, Bjerregaard B, Mejer J, Larsen FO, Pfeiffer P (2010) A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. Ann Oncol 21(1):87\u201391. doi: 10.1093\/annonc\/mdp272","journal-title":"Ann Oncol"},{"issue":"9079","key":"2558_CR28","first-page":"681","volume":"350","author":"F Levi","year":"1997","unstructured":"Levi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Int Organ Cancer Chronother Lancet 350(9079):681\u2013686","journal-title":"Int Organ Cancer Chronother Lancet"},{"issue":"3","key":"2558_CR29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(09)70381-X","volume":"11","author":"YJ Chua","year":"2010","unstructured":"Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I (2010) Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 11(3):241\u2013248. doi: 10.1016\/S1470-2045(09)70381-X","journal-title":"Lancet Oncol"},{"issue":"2","key":"2558_CR30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2007.12.7027","volume":"26","author":"ID Nagtegaal","year":"2008","unstructured":"Nagtegaal ID, Quirke P (2008) What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26(2):303\u2013312. doi: 10.1200\/JCO.2007.12.7027","journal-title":"J Clin Oncol"},{"issue":"2","key":"2558_CR31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/annonc\/mdj041","volume":"17","author":"A Paoli De","year":"2006","unstructured":"De Paoli A, Chiara S, Luppi G, Friso ML, Beretta GD, Del Prete S, Pasetto L, Santantonio M, Sarti E, Mantello G, Innocente R, Frustaci S, Corvo R, Rosso R (2006) Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 17(2):246\u2013251. doi: 10.1093\/annonc\/mdj041","journal-title":"Ann Oncol"},{"issue":"3\u20134","key":"2558_CR32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000127383","volume":"73","author":"O Dupuis","year":"2007","unstructured":"Dupuis O, Vie B, Lledo G, Hennequin C, Noirclerc M, Bennamoun M, Jacob JH (2007) Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR phase II study. Oncology 73(3\u20134):169\u2013176. doi: 10.1159\/000127383","journal-title":"Oncology"},{"issue":"15","key":"2558_CR33","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2011.39.7901","volume":"30","author":"IJ Park","year":"2012","unstructured":"Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ (2012) Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 30(15):1770\u20131776. doi: 10.1200\/JCO.2011.39.7901","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2558-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2558-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2558-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T17:05:39Z","timestamp":1565715939000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2558-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,8]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["2558"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2558-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,8]]}}}